Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04660812 · ClinicalTrials.gov registry record · Phase 1
An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.
A Phase 1 study of Metastatic Colorectal Cancer, sponsored by Arcus Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 227
- Enrollment target
- 20
- Study locations
NCT04660812: Completed Phase 1 study of Metastatic Colorectal Cancer, sponsored by Arcus Biosciences.
NCT04660812 is a Phase 1 study of Metastatic Colorectal Cancer that has completed, run by Arcus Biosciences. The registered enrollment target is 227 participants, above the 181-participant average among 45 other Metastatic Colorectal Cancer trials with a reported enrollment target (25% higher). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04660812, a Phase 1 study of Metastatic Colorectal Cancer, has completed, sponsored by Arcus Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 227 participants
- Enrollment target
- 20
- Study locations
Study Summary
This randomized phase 1b/2 open-label study will evaluate the antitumour activity and safety of etrumadenant (AB928) treatment combinations in participants with metastatic colorectal cancer.
Primary Outcome
PFS according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, as assessed by the Investigator
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Zimberelimab
- DRUG Etrumadenant
- DRUG AB680
- DRUG m-FOLFOX-6 regimen
Study Locations (20)
Other
- Institut Bergonie - Centre Regional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest - Bordeaux
- Centre Georges Francois Leclerc - Dijon
- Hopital Hotel Dieu - Nantes
California
- City of Hope Comprehensive Cancer Center - Duarte
- UCLA Hematology Oncology - Santa Monica
New York
- NYU Langone Medical Center - NYU Medical Oncology Associates - New York
- New York-Presbyterian Hospital-Columbia University Medical Center - New York
Tennessee
- Vanderbilt-Ingram Cancer Center - Nashville
- Sarah Cannon Research Institute - Nashville
Arizona
- Arizona Clinical Research Center Inc - Tucson
Connecticut
- Yale Cancer Center - New Haven
District of Columbia
- Sibley Memorial Hospital - Washington D.C.
Georgia
- Winship Cancer Institute at Emory University - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 227 participants |
| Start Date | 2021-05-10 |
| Est. Completion | 2025-09-05 |
| Phase | Phase 1 |
What the finished NCT04660812 record still lists
NCT04660812 is an interventional study that assigns participants to a tested intervention. The registered 227 participants enrollment target is mid-sized for trials with a published cap, above the 181-participant average among 45 other Metastatic Colorectal Cancer trials with a reported enrollment target (25% higher).
The record links to 1 condition, with Metastatic Colorectal Cancer appearing as the primary indexed condition, and to 5 interventions - of which Bevacizumab is the first listed.
NCT04660812 names 20 study sites across 15 states, led by Other, California, New York.
Frequently Asked Questions
What is clinical trial NCT04660812 about?
NCT04660812 is a clinical study titled "An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.". This randomized phase 1b/2 open-label study will evaluate the antitumour activity and safety of etrumadenant (AB928) treatment combinations in participants with metastatic colorectal cancer.
What is the current status of trial NCT04660812?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 227 participants. The study started on 2021-05-10. Estimated completion is 2025-09-05.
What conditions does trial NCT04660812 study?
This clinical trial studies the following conditions: Metastatic Colorectal Cancer.
What interventions are being tested in trial NCT04660812?
The interventions under investigation include: Bevacizumab (DRUG), Zimberelimab (DRUG), Etrumadenant (DRUG), AB680 (DRUG), m-FOLFOX-6 regimen (DRUG).
Who is sponsoring clinical trial NCT04660812?
This trial is sponsored by Arcus Biosciences, which has 25 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04660812 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, District of Columbia, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04660812's enrollment target sits among peer trials
227 14th of 45 higher than 32 of 45 other Metastatic Colorectal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Colorectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)
RECRUITING · Phase 1
-
Trial of ProAgio in Advanced/Metastatic Colorectal Cancer
RECRUITING · Phase 1
-
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations
RECRUITING · Phase 1
-
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04751409 · 227 participants · Phase 2
Evaluating the Impact of Limited Compared With Intense Post-Operative Surveillance on Patient-Reported Outcomes in Patients With Stage II-III Soft Tissue Sarcoma of the Trunk and Extremities
- NCT05742360 · 227 participants
Effect of CPAP on Blood Pressure in Excessively Sleepy Obstructive Sleep Apnea Subtype
- NCT05890352 · 227 participants · Phase 2
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
- NCT05107908 · 228 participants · NA
Neuronal and Behavioral Effects of an Implicit Priming Approach to Improve Eating Behaviors in Obesity
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI